Back to Treatments

Treatment

Immunotherapy (e.g., Pembrolizumab, Nivolumab)

1
Conditions
300
Trials
15K
Participants
45%
Average Safety

Condition Evidence

Esophageal cancer

300 trials · 15K participants

65% effectiveness · 45% safety
Immunotherapy (e.g., Pembrolizumab, Nivolumab) | DFDA